158 related articles for article (PubMed ID: 21387092)
1. Analysis of efficacy and cost-effectiveness of high-dose arabinoside versus daunorubicin chemotherapy in older adult patients with acute myeloid leukemia by cytogenetic risk profile: retrospective review from China.
Huang BT; Wang Y; Du QF; Yang J; Yu J; Zeng QC; Xu N; Zhang JF; Xu LL; Luo XJ; Wei YQ; Liu XL
Int J Hematol; 2011 Apr; 93(4):474-481. PubMed ID: 21387092
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of consolidation therapy with intermediate and high dose cytarabine in acute myeloid leukemia patients.
Tangchitpianvit K; Rattarittamrong E; Chai-Adisaksopha C; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Tantiworawit A; Norasetthada L
Hematology; 2021 Dec; 26(1):355-364. PubMed ID: 33853503
[TBL] [Abstract][Full Text] [Related]
3. Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia.
Fedele PL; Avery S; Patil S; Spencer A; Haas M; Wei A
Intern Med J; 2014 Aug; 44(8):757-63. PubMed ID: 24863325
[TBL] [Abstract][Full Text] [Related]
4. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.
List AF; Kopecky KJ; Willman CL; Head DR; Persons DL; Slovak ML; Dorr R; Karanes C; Hynes HE; Doroshow JH; Shurafa M; Appelbaum FR
Blood; 2001 Dec; 98(12):3212-20. PubMed ID: 11719356
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of postremission intensive therapy in patients with acute leukemia.
Yu YB; Gau JP; You JY; Chern HH; Chau WK; Tzeng CH; Ho CH; Hsu HC
Ann Oncol; 2007 Mar; 18(3):529-34. PubMed ID: 17164232
[TBL] [Abstract][Full Text] [Related]
6. Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia.
Benitez LL; Perissinotti AJ; Rausch CR; Klaus J; Clark SM; Filtz M; Ratermann K; Treptow C; Griffin S; Olson M; Crain M; Kadia T; Pettit K; Burke PW; Bixby DL; Marini BL
Leuk Lymphoma; 2021 Sep; 62(9):2184-2192. PubMed ID: 33830856
[TBL] [Abstract][Full Text] [Related]
7. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
Taub JW; Berman JN; Hitzler JK; Sorrell AD; Lacayo NJ; Mast K; Head D; Raimondi S; Hirsch B; Ge Y; Gerbing RB; Wang YC; Alonzo TA; Campana D; Coustan-Smith E; Mathew P; Gamis AS
Blood; 2017 Jun; 129(25):3304-3313. PubMed ID: 28389462
[TBL] [Abstract][Full Text] [Related]
8. Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin.
Seipelt G; Hofmann WK; Martin H; Wassmann B; Boehme A; Ottmann OG; Hoelzer D
Ann Hematol; 1998; 76(3-4):145-51. PubMed ID: 9619732
[TBL] [Abstract][Full Text] [Related]
9. Effect of postremission high dose cytarabine-based consolidation chemotherapy before allogenic stem cell transplantation in outcomes of acute myeloid leukemia patients.
Ciftciler R; Demiroglu H; Buyukasık Y; Okay M; Aksu S; Sayınalp N; Malkan UY; Haznedaroglu IC; Ozcebe O; Goker H
Transfus Apher Sci; 2018 Dec; 57(6):752-755. PubMed ID: 30249531
[TBL] [Abstract][Full Text] [Related]
10. High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature.
Kolla BC; Halim NAA; Cao Q; Sachs Z; Warlick E; Weisdorf D; Ho AYL; Chuan WG; Lao Z; He F
Br J Haematol; 2021 Jul; 194(1):140-144. PubMed ID: 33843048
[TBL] [Abstract][Full Text] [Related]
11. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study.
Miyawaki S; Ohtake S; Fujisawa S; Kiyoi H; Shinagawa K; Usui N; Sakura T; Miyamura K; Nakaseko C; Miyazaki Y; Fujieda A; Nagai T; Yamane T; Taniwaki M; Takahashi M; Yagasaki F; Kimura Y; Asou N; Sakamaki H; Handa H; Honda S; Ohnishi K; Naoe T; Ohno R
Blood; 2011 Feb; 117(8):2366-72. PubMed ID: 21190996
[TBL] [Abstract][Full Text] [Related]
12. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
[TBL] [Abstract][Full Text] [Related]
13. Age and cytogenetics as predictors of event free survival in patients with acute non-lymphocytic leukemia receiving high dose cytosine arabinoside and daunorubicin as consolidation chemotherapy.
Stein RS; Wolff SN; Greer JP; Flexner JM; Goodman S; Jagasia M; Brandt SJ; Morgan DS; Arrowsmith E; McCurley TL
Leuk Lymphoma; 2001; 42(5):913-22. PubMed ID: 11697646
[TBL] [Abstract][Full Text] [Related]
14. Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia.
Zhang W; Ding Y; Wu H; Chen Y; Lu H; Chen C; Fu J; Wang W; Liang A; Zou S
Medicine (Baltimore); 2014 Dec; 93(27):e134. PubMed ID: 25501050
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics.
Zhou JH; Lin HQ; Shen Q; Hu LN; Li GQ; Sun XF; Zhang XY
Curr Med Sci; 2018 Feb; 38(1):51-57. PubMed ID: 30074151
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of idarubicin/cytosine arabinoside versus daunorubicin/cytosine arabinoside in the treatment of adults with acute myeloid leukemia.
Pashko S; Jacobs J; Santorsa J
Clin Ther; 1991; 13(3):353-60. PubMed ID: 1954636
[TBL] [Abstract][Full Text] [Related]
17. The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience.
Huang BT; Zeng QC; Gurung A; Zhao WH; Xiao Z; Li BS
Med Oncol; 2012 Sep; 29(3):2088-94. PubMed ID: 22038728
[TBL] [Abstract][Full Text] [Related]
18. High Doses of Daunorubicin during Induction Therapy of Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Prospective Clinical Trials.
Gong Q; Zhou L; Xu S; Li X; Zou Y; Chen J
PLoS One; 2015; 10(5):e0125612. PubMed ID: 25993000
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype.
Mi Y; Xue Y; Yu W; Liu S; Zhao Y; Meng Q; Bian S; Wang J
Leuk Lymphoma; 2008 Mar; 49(3):524-30. PubMed ID: 18297530
[TBL] [Abstract][Full Text] [Related]
20. Impact of high dose cytarabine dosing strategies in obese patients with acute myeloid leukemia.
Ochs MA; Perissinotti AJ; Marini BL; Burke PW; Bixby DL; Pettit KM; Benitez LL
Leuk Res; 2021 Mar; 102():106517. PubMed ID: 33561633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
